Text Size

Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Disorder Mania

This study has been terminated.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by:
University Hospitals of Cleveland
ClinicalTrials.gov Identifier:
NCT00194064
First received: September 13, 2005
Last updated: December 5, 2007
Last verified: December 2007
History of Changes
  Purpose

Inpatient Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Mania: This study recruits adult subjects who are diagnosed with Bipolar I Disorder and presently experiencing an episode of mania. Patients must be willing to spend initial 7 days in the hospital to observe response to medication. Patients must be refractory (intolerant or non-responsive) to treatment with lithium and valproate or carbamazepine. Patients receive study-related care at no cost. This study is sponsored by Eli Lilly and Company.


Condition Intervention Phase
Bipolar Disorder
 Drug: Olanzapine
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Disorder Mania

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder
U.S. FDA Resources

Further study details as provided by University Hospitals of Cleveland:

Study Start Date: July 2002
Study Completion Date: February 2007
  Eligibility

Ages Eligible for Study:   16 Years to 65 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • The subject satisfied DSM-IV criteria for a primary diagnosis of Bipolar Disorder, most recently manic
  • The patient is willing to be hospitalized on an inpatient psychiatric unit for a minimum of seven (7) days.
  • Subject has been treated with lithium in the past.
  • Subject has been treated with divalproex or carbamazepine in the past.
  • The subject has not be treated with Haldol or haloperidol in the past.

Exclusion Criteria:

  • Subjects lacks the capacity to provide informed consent
  • Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators
  • Subject has been dependent on a druh (other than nicotine or caffeine) in the last three (3) months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00194064

Locations
United States, Ohio
University Hospitals of Cleveland
Cleveland, Ohio, United States, 44140
Sponsors and Collaborators
University Hospitals of Cleveland
Eli Lilly and Company
Investigators
Principal Investigator: Joseph R Calabrese, MD Case Western Reserve University / University Hospitals of Cleveland
  More Information

No publications provided

Responsible Party: Joseph R. Calabrese, University Hospitals/Case Western Reserve Unviersity
ClinicalTrials.gov Identifier: NCT00194064     History of Changes
Other Study ID Numbers: F1DMC-X136
Study First Received: September 13, 2005
Last Updated: December 5, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Olanzapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
 Therapeutic Uses
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents

ClinicalTrials.gov processed this record on May 16, 2013